HOME >> MEDICINE >> NEWS
St. John's wort ineffective for depression

DURHAM, N.C. The largest clinical trial performed to date on the popular herbal supplement St. John's wort (Hypericum perforatum) has found it to be no more effective than placebo for the treatment of a moderately severe form of major depression, according to researchers at Duke University Medical Center. Major depression, also called major depressive disorder, is one of the most common forms of depression.

Researchers designed the study to test the efficacy of St. John's wort (SJW) versus placebo for the treatment of major depression. In their study, they used the antidepressant sertraline (trade name Zoloft), which is a selective serotonin reuptake inhibitor (SSRI), as a "control" to measure the sensitivity of the study for detecting antidepressant effects of hypericum. SSRIs such as sertraline are a class of drug found to be effective in treating several forms of depression.

"Major depression is treatable, but this research suggests that major depression of at least moderate severity should not be treated with St. John's wort," said Jonathan R.T. Davidson, M.D., director of the Anxiety and Traumatic Stress Program at Duke and principal investigator of the study. "Rather than self-medicate with an over-the-counter medication or supplement, patients are strongly advised to consult an appropriate healthcare provider to assess the best treatment for a depressive episode."

Another author on the study, Robert Califf, M.D., director of the Duke Clinical Research Institute, emphasized the dangers of inadequate studies of St. John's wort and other herbal remedies.

"As long as these types of products remain available to the public without the protection of adequate, controlled and unbiased studies, taking them is like playing Russian roulette with your health," he said.

Study results appear in the April 10, 2002 issue of the Journal of the American Medical Association. Duke University Medical Center, Duke Clinical Research Institute (DCRI)
'"/>

Contact: Tracey Koepke
koepk002@mc.duke.edu
919-684-4148
Duke University
9-Apr-2002


Page: 1 2 3 4 5

Related medicine news :

1. St. Johns wort amplifies effect of blood thinner Plavix
2. The effects of St. Johns Wort (Hypericum perforatum)
3. UT Southwestern Study To Test Efficacy Of St. Johns Wort For Treatment Of Depression
4. Study Finds St. Johns Wort Can Cut Alcohol Consumption
5. Government wasting your taxpayer money on ineffective drug cure
6. School-based smoking prevention programs ineffective
7. Surgical procedure to treat GERD in children found to be ineffective
8. Fetal heart monitoring ineffective at diagnosing cerebral palsy
9. Doubling of steroid before severe asthma attack ineffective
10. Promising drug proves ineffective as treatment for hearing loss
11. Screening children for speech problems is ineffective

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... , ... March 27, 2017 , ... ... that for a second year in a row; they are the recipient of ... in the industry voted on the award at Design Connections 2017. Top A&D ...
(Date:3/27/2017)... California (PRWEB) , ... March 27, 2017 , ... The ... to its customers. First National Capital has added 10 new sales professionals over the ... its sales positions by 15 additional new hires over the course of 2017. ...
(Date:3/27/2017)... ... March 27, 2017 , ... Golden Triangle Emergency Center will ... April 3rd to commemorate the two-year anniversary of the facility. The event will ... two great years while also familiarizing themselves with the facility. , In the ...
(Date:3/26/2017)... ... March 26, 2017 , ... Local physician Dr. Justin Harper ... prestigious award honoring the top influencers on RealSelf—the most trusted online destination to ... and clinics. , In 2016, more than 82 million people visited RealSelf to ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... at the same time by providing Prehospital Trauma Life Support (PHTLS) course scholarships ... world’s premier prehospital trauma education developed in cooperation with the American College of ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... LightIntegra Technology Inc. today announced that its ... President and Chief Executive Officer effective March 13, 2017. ... Directors of LightIntegra. Paul Geyer will continue ... "This is the perfect time for Bill ... We,ve selected a very strong leader at a time ...
(Date:3/27/2017)... VANCOUVER, British Columbia, March 27, 2017  Sophiris ... "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company ... with urological diseases, today reported fourth quarter and ... highlights. Key Corporate Highlights: ... for Localized Prostate Cancer. During 2016, the Company ...
(Date:3/27/2017)... , March 27, 2017   Pulmatrix, Inc . ... therapies to address serious pulmonary diseases, today announced that it ... disease, cystic fibrosis and asthma to its Scientific Advisory ... Richard B. Moss , MD, former chief ... of the Cystic Fibrosis Center at Stanford University, and ...
Breaking Medicine Technology:
Cached News: